Reply: Dual Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Do We Have Enough Evidence?
作者信息
Singal Aayush Kumar, Singh Avinainder, Bansal Raghav, Mishra Sundeep
出版信息
JACC CardioOncol. 2022 Mar 15;4(1):144-145. doi: 10.1016/j.jaccao.2022.02.005. eCollection 2022 Mar.
Abstract
摘要
相似文献
1
Reply: Dual Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Do We Have Enough Evidence?
JACC CardioOncol. 2022 Mar 15;4(1):144-145. doi: 10.1016/j.jaccao.2022.02.005. eCollection 2022 Mar.
2
Transthyretin Cardiac Amyloidosis and Aortic Stenosis: Connection and Therapeutic Implications.转甲状腺素蛋白心脏淀粉样变性与主动脉瓣狭窄：关联及治疗意义
Curr Cardiol Rev. 2020;16(3):221-230. doi: 10.2174/1573403X15666190722154152.
3
Subthreshold Aortic Valve Calcium Scores in Severe Aortic Stenosis and Transthyretin Cardiac Amyloidosis.重度主动脉瓣狭窄和转甲状腺素蛋白心脏淀粉样变中的亚阈值主动脉瓣钙评分
JACC Case Rep. 2020 Nov 18;2(14):2205-2209. doi: 10.1016/j.jaccas.2020.10.002.
4
[Wild-type transthyretin-related cardiac amyloidosis and degenerative aortic stenosis: Two inter-related pathologies in the elderly].[野生型转甲状腺素蛋白相关心脏淀粉样变性与退行性主动脉瓣狭窄：老年人中的两种相关病理情况]
Rev Esp Geriatr Gerontol. 2017 May-Jun;52(3):167-170. doi: 10.1016/j.regg.2016.05.002. Epub 2016 Jun 10.
5
Transthyretin cardiac amyloidosis in aortic stenosis: Prevalence, diagnostic challenges, and clinical implications.心脏转甲状腺素蛋白淀粉样变合并主动脉瓣狭窄：患病率、诊断挑战及临床意义。
Hellenic J Cardiol. 2020 Mar-Apr;61(2):92-98. doi: 10.1016/j.hjc.2019.10.004. Epub 2019 Nov 15.
6
Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement.严重钙化性主动脉瓣狭窄中的隐匿性转甲状腺素蛋白心脏淀粉样变：接受外科主动脉瓣置换术患者的患病率及预后
Circ Cardiovasc Imaging. 2016 Aug;9(8). doi: 10.1161/CIRCIMAGING.116.005066.
7
Antegrade Balloon Aortic Valvuloplasty for the Highly Frail Patient of Severe Aortic Stenosis Complicated with Transthyretin-type Cardiac Amyloidosis.顺行球囊主动脉瓣成形术治疗合并转甲状腺素蛋白型心脏淀粉样变性的重度主动脉瓣狭窄高龄体弱患者
Intern Med. 2020 Apr 15;59(8):1053-1057. doi: 10.2169/internalmedicine.3870-19. Epub 2019 Dec 26.
8
Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis.揭示并存严重主动脉瓣狭窄和转甲状腺素蛋白心脏淀粉样变性的结果。
Eur J Heart Fail. 2021 Feb;23(2):250-258. doi: 10.1002/ejhf.1974. Epub 2020 Sep 8.
9
Aortic Stenosis and Cardiac Amyloidosis: JACC Review Topic of the Week.主动脉瓣狭窄与心脏淀粉样变性：美国心脏病学会评论专题周报
J Am Coll Cardiol. 2019 Nov 26;74(21):2638-2651. doi: 10.1016/j.jacc.2019.09.056.
10
Aortic stenosis, transcatheter aortic valve replacement and transthyretin cardiac amyloidosis: are we progressively unraveling the tangle?主动脉瓣狭窄、经导管主动脉瓣置换术与转甲状腺素蛋白心脏淀粉样变性：我们是否正在逐步解开这一难题？
Eur J Heart Fail. 2021 Feb;23(2):259-263. doi: 10.1002/ejhf.2057. Epub 2020 Nov 25.
本文引用的文献
1
Prevalence and outcomes of concomitant cardiac amyloidosis and aortic stenosis: A systematic review and meta-analysis.同时患有心脏淀粉样变性和主动脉瓣狭窄的患病率和结局：系统评价和荟萃分析。
Hellenic J Cardiol. 2022 Mar-Apr;64:67-76. doi: 10.1016/j.hjc.2021.11.001. Epub 2021 Nov 29.
2
Concomitant Transthyretin Amyloidosis and Severe Aortic Stenosis in Elderly Indian Population: A Pilot Study.印度老年人群中伴发甲状腺素运载蛋白淀粉样变与严重主动脉瓣狭窄：一项初步研究
JACC CardioOncol. 2021 Oct 19;3(4):565-576. doi: 10.1016/j.jaccao.2021.08.008. eCollection 2021 Oct.
3
Transthyretin amyloidosis in aortic stenosis: clinical and therapeutic implications.主动脉瓣狭窄中的转甲状腺素蛋白淀粉样变性：临床及治疗意义
Eur Heart J Suppl. 2021 Oct 8;23(Suppl E):E128-E132. doi: 10.1093/eurheartj/suab107. eCollection 2021 Oct.
4
Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.心脏转甲状腺素蛋白淀粉样变性的自然病史、生活质量和结局。
Circulation. 2019 Jul 2;140(1):16-26. doi: 10.1161/CIRCULATIONAHA.118.038169. Epub 2019 May 21.
5
Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.系统性心脏淀粉样变：3种主要类型的疾病特征与临床病程
Circulation. 2009 Sep 29;120(13):1203-12. doi: 10.1161/CIRCULATIONAHA.108.843334. Epub 2009 Sep 14.
Zotero 插件